Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMM02-KORA in PD-associated Dyskinesia
NCT07905976Phase 1Not yet recruiting
- Sponsor
- Immunis, Inc.
- Start
- Nov 2026
- Primary completion
- Dec 2027
01
Overview
Phase 1, open-label trial of IMM02-KORA in levodopa-induced dyskinesia (LID) (2 arms), sponsored by Immunis, Inc. Primary endpoint: Incidence and severity of treatment-emergent adverse events and Dose Limiting Toxicity at 15 weeks. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
IMM02-KORA
03
Conditions
levodopa-induced dyskinesia (LID)
Beyond the preview
Go deeper on NCT07905976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07905976.